---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000018"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:56:08.928729+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion reports Q4 net loss of $93M, cash $391.6M; '24 clinical data readouts planned

## Summary
- Net loss $93M in Q4 2023 vs $57.5M a year ago; full-year loss $328.1M vs $239.5M.
- Cash and equivalents $391.6M at Dec 31, 2023, down from $549.9M a year earlier.
- R&D expenses rose to $69.5M in Q4 from $44M; operating cash burn $287.8M for 2023.
- Key clinical milestones: REC-994 Phase 2 data Q3 2024; REC-2282 data Q4 2024; REC-3964 Phase 2 start in 2024.
- Named Kristen Rushton as Chief Business Operations Officer; in-licenced Bayer fibrosis program (Target Epsilon) entering IND-enabling.

## SEC filing metadata
- accession: 0001601830-24-000018
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/0001601830-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/rxrx-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000018
- JSON: https://secwatch.observer/filing/0001601830-24-000018.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000018.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000018/0001601830-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.